Association of Facial Pustular Neutrophilic Eruption With Messenger RNA-1273 SARS-CoV-2 Vaccine

JAMA Dermatol. 2021 Sep 1;157(9):1128-1130. doi: 10.1001/jamadermatol.2021.2474.

Authors

Eric Dean Merrill¹, Sakeen W Kashem¹, Erin H Amerson^{1

2}, Laura B Pincus^{1

3}, Ursula E Lang^{1

2

3}, Kanade Shinkai¹, Aileen Y Chang^{1

2}

Affiliations

¹ Department of Dermatology, University of California, San Francisco.
² Department of Dermatology, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California.
³ Dermatopathology Service, Departments of Dermatology and Pathology, University of California, San Francisco.

PMID: 34319363
DOI: 10.1001/jamadermatol.2021.2474

No abstract available

Publication types

Case Reports

MeSH terms

2019-nCoV Vaccine mRNA-1273
Aged, 80 and over
Anti-Bacterial Agents / administration & dosage
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines / adverse effects*
Dermatologic Agents / administration & dosage
Diagnosis, Differential
Drug Eruptions / diagnosis*
Drug Eruptions / drug therapy
Drug Eruptions / immunology
Drug Eruptions / pathology
Drug Therapy, Combination
Facial Dermatoses / diagnosis*
Facial Dermatoses / drug therapy
Facial Dermatoses / immunology
Facial Dermatoses / pathology
Humans
Male
Middle Aged
Neutrophils / immunology*
Rosacea / diagnosis
SARS-CoV-2 / genetics
SARS-CoV-2 / immunology
Skin / immunology
Skin / pathology
Treatment Outcome

Substances

Anti-Bacterial Agents
COVID-19 Vaccines
Dermatologic Agents
2019-nCoV Vaccine mRNA-1273